上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
S2157
S2157 是 N-烷基化的反式环丙胺 (TCP) 衍生物，是一种有效的赖氨酸特异性脱甲基酶 1 (LSD1) 抑制剂。S2157 在超级增强子区域增加 H3K9 甲基化和相应的 H3K27 脱乙酰化。S2157 抑制 NOTCH3 和 TAL1 基因的转录，从而诱导 TCP 抵抗性急性淋巴细胞白血病 T-ALL 细胞凋亡 (apoptosis)。S2157 有效地透过血脑屏障，几乎可以完全根除 T-ALL 细胞移植小鼠的中枢神经系统白血病。
S2157 Chemical Structure
CAS No. : 2262488-39-9
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells[1].
|
IC50 & Target |
|
体外研究
(In Vitro) |
S2157 is particularly effective for T-ALL cell lines with the IC50 values between 1.1 µM for human T-ALL cell lines CEM and 6.8 µM for MOLT4[1].
S2157 (4-20 µM; 72 hours) modestly inhibits mitogen-activated normal T-lymphocytes[1].
S2157 (4-8 µM; 24 hours) induces apoptosis and down-regulates the expression of NOTCH3 and TAL1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) cells[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[1]
| Cell Line: |
Normal T-lymphocytes |
| Concentration: |
4, 8, 12, 16, 20 µM |
| Incubation Time: |
For 72 hours |
| Result: |
Modestly inhibited mitogen-activated normal T-lymphocytes. |
Apoptosis Analysis[1]
| Cell Line: |
T-cell acute lymphoblastic leukemia (T-ALL) cells |
| Concentration: |
4, 6, 8 µM |
| Incubation Time: |
For 24 hours |
| Result: |
Induced apoptosis, as evidenced by increased annexin-V reactivity on flow cytometry in T-ALL cells in a dose- and time-dependent manner without affecting cell cycle distribution. |
Western Blot Analysis[1]
| Cell Line: |
T-ALL cells |
| Concentration: |
4, 6, 8 µM |
| Incubation Time: |
For 24 hours |
| Result: |
Down-regulated the expression of NOTCH3 and TAL1 proteins in T-ALL cells. |
|
体内研究
(In Vivo) |
S2157 (50 mg/kg; IP; 3 times a week; for 28 days) causes the size of subcutaneous tumors reduced to less than 20% of that in the untreated control[1].
S2157 (50 mg/kg; IP) has a T1/2 of 0.88 hours, a Cmax of 4.33 μM and an AUC of 5.75 μM•h[1].
S2157 (30 mg/kg or 50 mg/kg; twice a week for 3 weeks) almost completely suppressed the growth of MOLT4 cells in most but not all NOD/SCID mice with MOLT4 cells. S2157 eradicates CNS leukemia in murine xenotransplanted models[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with MOLT4 cells[1] |
| Dosage: |
50 mg/kg |
| Administration: |
IP; 3 times a week; for 28 days |
| Result: |
The size of subcutaneous tumors reduced to less than 20% of that in the untreated control. |
| Animal Model: |
8-week-old ICR mice[1] |
| Dosage: |
50 mg/kg (Pharmacokinetic Analysis) |
| Administration: |
IP |
| Result: |
Had a T1/2 of 0.88 hours, a Cmax of 4.33 μM and an AUC of 5.75 μM•h. |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
